- Ministry of Health (MOH) — Policy and oversight
Israeli Ministry of Health sets national medical cannabis policy. Oversees IMFA. Issues the legal framework under the Dangerous Drugs Ordinance and MOH directives.
- National cannabis policy framework
- Oversight of IMFA licensing program
- Patient access policy — quota setting
- IMFA — Israel Medical Cannabis Agency
Primary regulatory authority for medical cannabis in Israel. Issues all IMCA licenses (cultivation, manufacturing, distribution, export, dispensing). Conducts GMP/GACP inspections.
- Issues IMCA licenses across supply chain
- GMP inspections — IMFA-issued certificates accepted by EU, UK, AUS, CA
- Per-shipment export permits
- Domestic patient quota management
- IMFA — GMP Inspectorate — Manufacturing oversight
IMFA GMP inspections are conducted to a standard that is bilaterally recognized by the EMA network, MHRA, TGA, and Health Canada. IMFA GMP certificates are the primary credential for Israeli export.
- EU-GMP Part I and Part II inspections conducted
- Bilateral recognition with EMA, MHRA, TGA
- Cannabis-specific GMP scope required
- IMFA — Licensing — IMCA license management
Issues all IMCA licenses. Currently ~120 licensed entities in Israel across cultivation, manufacturing, and distribution. License renewal is annual.
- Cultivation licenses (indoor, outdoor, greenhouse)
- Manufacturing licenses (finished product, API, extract)
- Distribution and export licenses
- Licensed Manufacturers — IMCA holders
~60 active manufacturing license holders in Israel as of 2026. Most are vertically integrated (cultivation + manufacturing). EU-GMP certification is near-universal among export-oriented manufacturers.
- IMCA manufacturing license
- EU-GMP Part I or Part II certificate
- GACP certificate for cultivation site
- Batch release by qualified person
- Licensed Pharmacies / Dispensaries — Domestic dispensing
IMFA-licensed pharmacies and cannabis dispensaries. Domestic patients receive cannabis via prescription against MOH quota. Strict chain of custody from manufacturer to patient.
- IMFA dispensing license
- Patient prescription and quota management
- Cold chain if applicable
- Monthly reporting to IMFA
- Patients (Domestic) — ~120,000 licensed patients
Israel has approximately 120,000 licensed medical cannabis patients as of 2026 — one of the highest per-capita rates globally. Patients receive a government quota and purchase from licensed dispensaries or pharmacies.